Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.25), which may not compare with the analyst estimate of ($0.20). Revenue for the quarter came in at $5.94 million versus the consensus estimate of $6.96 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.